ONCOMATRYX raised $67 million to advance clinical development of its Quantum ADC drugs in Spain.
- Amount
- $67M
- Announced
- 30 March 2026
- Investors
- Centro para el Desarrollo Tecnologico e Innovacion (CDTI), Kutxa Fundazioa, Basque Government (Gobierno Vasco), Ekarpen VC, BBK
- Use of funds
- Fostering clinical development of novel candidates, including taking OMTX105 and other Quantum ADCs into clinical trials.
- Checked
- Amount and date checked against the press source